New eye drop JN002 aims to soothe dry eyes in early human test
NCT ID NCT07245017
First seen Nov 28, 2025 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This early study tests a new eye drop called JN002 in 30 adults with dry eye disease. Participants will use the drops three times a day for 28 days. The goal is to see if the drops are safe and if they improve symptoms and eye surface health compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eye & ENT Hospital of Fudan University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JN002 ophthalmic solution
What this could lead to
If it works, this could point toward a new eye drop to relieve dry eye symptoms and reduce eye surface damage.
What could go wrong
This is a very early, small trial with only 30 people. It is designed mainly to check safety, not prove effectiveness. The results may not lead to a treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.